160 related articles for article (PubMed ID: 12754528)
21. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
22. [Infection in neutropenic cancer patients--etiology, microbiological diagnostics, treatment].
Durnaá B; Dzierzanowska D
Wiad Lek; 2006; 59(7-8):506-11. PubMed ID: 17209349
[TBL] [Abstract][Full Text] [Related]
23. Risk assessment and microbiological profile of infections in paediatric cancer patients with febrile neutropenia.
Latiff Z; Zulkifli SZ; Jamal R
Malays J Pathol; 2002 Dec; 24(2):83-9. PubMed ID: 12887165
[TBL] [Abstract][Full Text] [Related]
24. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
25. A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility.
Sigurdardottir K; Digranes A; Harthug S; Nesthus I; Tangen JM; Dybdahl B; Meyer P; Hopen G; Løkeland T; Grøttum K; Vie W; Langeland N
Scand J Infect Dis; 2005; 37(6-7):455-64. PubMed ID: 16012006
[TBL] [Abstract][Full Text] [Related]
26. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
27. Drug therapy management of the febrile neutropenic cancer patient.
Finkbiner KL; Ernst TF
Cancer Pract; 1993; 1(4):295-304. PubMed ID: 8111439
[TBL] [Abstract][Full Text] [Related]
28. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia.
Rolston KV
Clin Infect Dis; 2005 Apr; 40 Suppl 4():S246-52. PubMed ID: 15768330
[TBL] [Abstract][Full Text] [Related]
29. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
30. Management of fever in neutropenic patients with different risks of complications.
Klastersky J
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S32-7. PubMed ID: 15250018
[TBL] [Abstract][Full Text] [Related]
31. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Hori A; Kami M; Kim SW; Chizuka A; Kojima R; Imataki O; Sakiyama M; Hamaki T; Onishi Y; Usubuchi N; Kishi Y; Murashige N; Tajima K; Miyakoshi S; Heike Y; Masuo S; Taniguchi S; Takaue Y
Biol Blood Marrow Transplant; 2004 Jan; 10(1):65-72. PubMed ID: 14752781
[TBL] [Abstract][Full Text] [Related]
32. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
33. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols.
Greenberg D; Moser A; Yagupsky P; Peled N; Hofman Y; Kapelushnik J; Leibovitz E
Int J Antimicrob Agents; 2005 Jun; 25(6):469-73. PubMed ID: 15890499
[TBL] [Abstract][Full Text] [Related]
34. [Principal infections in the oncology patient: practical treatment].
Fortún J
An Sist Sanit Navar; 2004; 27 Suppl 3():17-31. PubMed ID: 15723102
[TBL] [Abstract][Full Text] [Related]
35. Bacterial infections in low-risk, febrile neutropenic patients.
Kamana M; Escalante C; Mullen CA; Frisbee-Hume S; Rolston KV
Cancer; 2005 Jul; 104(2):422-6. PubMed ID: 15937905
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Leibovici L; Paul M; Cullen M; Bucaneve G; Gafter-Gvili A; Fraser A; Kern WV
Cancer; 2006 Oct; 107(8):1743-51. PubMed ID: 16977651
[TBL] [Abstract][Full Text] [Related]
37. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
38. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes.
Bow EJ
Semin Hematol; 2009 Jul; 46(3):259-68. PubMed ID: 19549578
[TBL] [Abstract][Full Text] [Related]
39. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
40. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
